APL 2

Drug Profile

APL 2

Alternative Names: APL2

Latest Information Update: 04 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Apellis Pharmaceuticals
  • Class Antianaemics; Cyclic peptides; Eye disorder therapies
  • Mechanism of Action Complement C3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Paroxysmal nocturnal haemoglobinuria
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Autoimmune haemolytic anaemia; Dry age-related macular degeneration
  • Phase I Ischaemia; Paroxysmal nocturnal haemoglobinuria; Wet age-related macular degeneration

Most Recent Events

  • 28 Sep 2017 Apellis Pharmaceuticals initiate a phase I trial in Paroxysmal nocturnal haemoglobinuria (In volunteers) in Australia (ACTRN12617000982314p)
  • 31 Aug 2017 Phase-II clinical trials in Autoimmune haemolytic anaemia in USA (SC) (NCT03226678)
  • 29 Aug 2017 Apellis Pharmaceuticals completes enrolment in the phase II FILLY trial for Dry age-related macular degeneration in USA, Australia and New Zealand before August 2017 (NCT02503332)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top